MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
8.21
+1.08
+15.15%
After Hours: 8.40 +0.19 +2.31% 18:40 02/03 EST
OPEN
7.15
PREV CLOSE
7.13
HIGH
8.50
LOW
7.15
VOLUME
220.42K
TURNOVER
0
52 WEEK HIGH
15.54
52 WEEK LOW
6.05
MARKET CAP
397.36M
P/E (TTM)
-3.7852
1D
5D
1M
3M
1Y
5Y
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 01/09 18:42
BRIEF-Monte Rosa Therapeutics Outlines Progress Across Portfolio Of Molecular Glue Degraders
Reuters · 01/09 12:50
Monte Rosa Therapeutics Outlined Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
Benzinga · 01/09 12:38
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Announces $19 Price Target
Benzinga · 01/03 09:36
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18
MT Newswires · 01/03 07:59
Dow Surges 150 Points; Crude Oil Falls Sharply
Benzinga · 11/14/2022 19:34
Monte Rosa Therapeutics GAAP EPS of -$0.58 beats by $0.02
Seekingalpha · 11/10/2022 14:27
BRIEF-Monte Rosa Therapeutics Reports Third Quarter Results
Reuters · 11/10/2022 13:07
More
About GLUE
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company. It is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.

Webull offers kinds of Monte Rosa Therapeutics Inc stock information, including NASDAQ:GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.